GlassScriptPhysician profile
Reece A Jones
NPI 1538401203
$8,645.91
in general payments reported to CMS, 2019-2025
43 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $807 · 2021: $513 · 2022: $973 · 2023: $1,485 · 2024: $1,797 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,284 · Honoraria: $350 · Education: $268 · Consulting Fee: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,283.98 |
| Honoraria | $350.00 |
| Education | $268.44 |
| Consulting Fee | $140.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,596.00 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,161.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $810.36 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $675.74 | 2019-2025 | Dupixent |
| Csl Behring | $400.13 | 2019-2025 | Hizentra, Haegarda |
| Genzyme Corporation | $387.60 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $377.24 | 2020-2024 | |
| Pharming Healthcare, INC. | $291.18 | 2019-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $260.31 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $230.91 | 2019-2020 | |
| Daiichi Sankyo INC. | $221.33 | 2021-2025 | Enhertu |
| Optinose US, INC. | $187.09 | 2019-2024 | |
| Kaleo, INC. | $158.87 | 2019-2024 | Auvi-Q |
| Greer Laboratories, INC. | $154.82 | 2019-2025 | Oralair |
| Genentech USA, INC. | $151.99 | 2019-2024 | Xolair, Columvi, Polivy |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reece Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.